November 19, 2021
A group with antitrust claims against Mallinckrodt on Friday asked a Delaware bankruptcy judge to appoint an examiner to investigate what it claims are thousands of questionable votes cast for the drugmaker's Chapter 11 plan on behalf of asbestos injury claimants.
November 18, 2021
The Delaware bankruptcy judge overseeing Mallinckrodt's Chapter 11 case Thursday granted requests to delay the resumption of the drugmaker's plan confirmation hearing, saying he first needs to digest claims it engaged in drug price manipulation.
November 17, 2021
Mallinckrodt closed its defense against claims it inflated the price of its Acthar gel on Wednesday, with witnesses saying that the drugmaker didn't suppress a competing product and that the speaking fees it paid to doctors didn't increase sales.
November 16, 2021
An expert witness for Mallinckrodt told a Delaware bankruptcy judge Tuesday that two insurers seeking more than $317 million in damages wouldn't be owed any more than $2.6 million even if their claims that the drugmaker suppressed competition for its Acthar gel were true.
November 15, 2021
A Mallinckrodt executive defended the pricing and marketing of the drugmaker's Acthar gel on Monday as a pair of insurers presented a Delaware judge with the last of their evidence that Mallinckrodt engaged in a yearslong scheme to drive up Acthar's cost.
November 12, 2021
A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid more than $320 million for Acthar over the past year.
November 08, 2021
A pair of health insurers told a Delaware bankruptcy judge Monday that Mallinckrodt PLC owes them more than $300 million because of the drugmaker's alleged efforts to keep a cheaper alternative to its Acthar infantile spasm drug off the market.
November 05, 2021
A Delaware bankruptcy judge on Friday found Mallinckrodt does not owe a $94 million payment to noteholders, saying the creditors should not get a "windfall" simply as a result of the drugmaker's Chapter 11 filing.
November 04, 2021
A bankruptcy judge in Delaware Thursday ruled drugmaker Mallinckrodt can use Chapter 11 to escape royalty payments for the sale of its Acthar Gel medication as the confirmation hearing for the company's restructuring plan continued.
November 02, 2021
A group with antitrust claims against drugmaker Mallinckrodt challenged the vote approving the company's Chapter 11 plan on Tuesday, but lost a bid to get counsel for the unsecured creditors on the stand to address the vote solicitation process.